{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T17:19:50Z","timestamp":1795281590552,"version":"4.10.3"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100001298","name":"Presbyterian Health Foundation","doi-asserted-by":"publisher","award":["Bridge"],"award-info":[{"award-number":["Bridge"]}],"id":[{"id":"10.13039\/100001298","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001298","name":"Presbyterian Health Foundation","doi-asserted-by":"publisher","award":["Bridge"],"award-info":[{"award-number":["Bridge"]}],"id":[{"id":"10.13039\/100001298","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001298","name":"Presbyterian Health Foundation","doi-asserted-by":"publisher","award":["Bridge"],"award-info":[{"award-number":["Bridge"]}],"id":[{"id":"10.13039\/100001298","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001298","name":"Presbyterian Health Foundation","doi-asserted-by":"publisher","award":["Bridge"],"award-info":[{"award-number":["Bridge"]}],"id":[{"id":"10.13039\/100001298","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001298","name":"Presbyterian Health Foundation","doi-asserted-by":"publisher","award":["Bridge"],"award-info":[{"award-number":["Bridge"]}],"id":[{"id":"10.13039\/100001298","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Cancer Institute (NCI) Cancer Center Support Grant","award":["P30CA225520"],"award-info":[{"award-number":["P30CA225520"]}]},{"name":"National Cancer Institute (NCI) Cancer Center Support Grant","award":["P30CA225520"],"award-info":[{"award-number":["P30CA225520"]}]},{"name":"National Cancer Institute (NCI) Cancer Center Support Grant","award":["P30CA225520"],"award-info":[{"award-number":["P30CA225520"]}]},{"name":"National Cancer Institute (NCI) Cancer Center Support Grant","award":["P30CA225520"],"award-info":[{"award-number":["P30CA225520"]}]},{"name":"National Cancer Institute (NCI) Cancer Center Support Grant","award":["P30CA225520"],"award-info":[{"award-number":["P30CA225520"]}]},{"name":"National Cancer Institute (NCI) Cancer Center Support Grant","award":["P30CA225520"],"award-info":[{"award-number":["P30CA225520"]}]},{"name":"National Cancer Institute (NCI) Cancer Center Support Grant","award":["P30CA225520"],"award-info":[{"award-number":["P30CA225520"]}]},{"DOI":"10.13039\/100024521","name":"Oklahoma Tobacco Settlement Endowment Trust","doi-asserted-by":"publisher","award":["R23-02"],"award-info":[{"award-number":["R23-02"]}],"id":[{"id":"10.13039\/100024521","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100024521","name":"Oklahoma Tobacco Settlement Endowment Trust","doi-asserted-by":"publisher","award":["R23-02"],"award-info":[{"award-number":["R23-02"]}],"id":[{"id":"10.13039\/100024521","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100024521","name":"Oklahoma Tobacco Settlement Endowment Trust","doi-asserted-by":"publisher","award":["R23-02"],"award-info":[{"award-number":["R23-02"]}],"id":[{"id":"10.13039\/100024521","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100024521","name":"Oklahoma Tobacco Settlement Endowment Trust","doi-asserted-by":"publisher","award":["R23-02"],"award-info":[{"award-number":["R23-02"]}],"id":[{"id":"10.13039\/100024521","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100024521","name":"Oklahoma Tobacco Settlement Endowment Trust","doi-asserted-by":"publisher","award":["R23-02"],"award-info":[{"award-number":["R23-02"]}],"id":[{"id":"10.13039\/100024521","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>What drives inflammation-associated tumorigenesis and progression in pancreatic ductal adenocarcinoma (PDAC)? Doublecortin-like kinase 1 (DCLK1) is a central driver of inflammation-associated tumorigenesis, with elevated expression linked to worse clinical outcomes. Two isoforms of DCLK1 possess a unique extracellular domain (ECD). DCLK1 isoform 2 contains two microtubule-binding domains, while isoform 4, lacks the microtubule-binding domains but, plays a pivotal role in tumor progression. We identified novel D-peptides that selectively target this ECD, significantly suppressing PDAC cell proliferation in vitro and tumor growth in xenograft models without inducing cell death. In silico modeling and binding assays revealed DCLK1 isoform 4 interacts with pro-tumorigenic proteins like plasma gelsolin (pGSN), with D-peptides modulating these interactions. These findings underscore DCLK1\u2019s non-kinase functions as a therapeutic target and highlight novel avenues for developing precision treatments aimed at halting cancer progression and improving patient outcomes.<\/jats:p>","DOI":"10.1038\/s41598-025-19722-z","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T14:44:48Z","timestamp":1760453088000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A novel D-peptide modulates DCLK1 gelsolin interactions, reducing PDAC tumor growth"],"prefix":"10.1038","volume":"15","author":[{"given":"Landon L.","family":"Moore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongfeng","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parthasarathy","family":"Chandrekesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamille","family":"Pitts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randal","family":"May","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byron E.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milton L.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney W.","family":"Houchen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"key":"19722_CR1","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3892\/ijo.2022.5427","volume":"61","author":"Q Lu","year":"2022","unstructured":"Lu, Q. et al. Role of DCLK1 in oncogenic signaling (Review). Int. J. Oncol. 61, 137. https:\/\/doi.org\/10.3892\/ijo.2022.5427 (2022).","journal-title":"Int. J. Oncol."},{"key":"19722_CR2","doi-asserted-by":"publisher","DOI":"10.4172\/2157-2518.1000257","author":"P Chandrakesan","year":"2016","unstructured":"Chandrakesan, P. et al. Regulatory roles of Dclk1 in epithelial mesenchymal transition and cancer stem cells. J. Carcinog. Mutagen. https:\/\/doi.org\/10.4172\/2157-2518.1000257 (2016).","journal-title":"J. Carcinog. Mutagen."},{"key":"19722_CR3","first-page":"36","volume":"6","author":"AR Safa","year":"2020","unstructured":"Safa, A. R. Epithelial-mesenchymal transition: A hallmark in pancreatic cancer stem cell migration, metastasis formation, and drug resistance. J. Cancer Metastasis Treat. 6, 36 (2020).","journal-title":"J. Cancer Metastasis Treat."},{"key":"19722_CR4","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1158\/0008-5472.CAN-10-2738","volume":"71","author":"SM Sureban","year":"2011","unstructured":"Sureban, S. M. et al. DCAMKL-1 regulates epithelial-mesenchymal transition in human pancreatic cells through a miR-200a-dependent mechanism. Cancer Res. 71, 2328\u20132338. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-2738 (2011).","journal-title":"Cancer Res."},{"key":"19722_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41589-020-0506-0","author":"FM Ferguson","year":"2020","unstructured":"Ferguson, F. M. et al. Discovery of a selective inhibitor of doublecortin like kinase 1. Nat. Chem. Biol. https:\/\/doi.org\/10.1038\/s41589-020-0506-0 (2020).","journal-title":"Nat. Chem. Biol."},{"key":"19722_CR6","doi-asserted-by":"publisher","first-page":"17696","DOI":"10.1074\/jbc.M111981200","volume":"277","author":"HA Burgess","year":"2002","unstructured":"Burgess, H. A. & Reiner, O. Alternative splice variants of doublecortin-like kinase are differentially expressed and have different kinase activities. J. Biol. Chem. 277, 17696\u201317705. https:\/\/doi.org\/10.1074\/jbc.M111981200 (2002).","journal-title":"J. Biol. Chem."},{"key":"19722_CR7","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1002\/ijc.31400","volume":"143","author":"Y Ge","year":"2018","unstructured":"Ge, Y. et al. Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer. Int. J. Cancer. 143, 1162\u20131175. https:\/\/doi.org\/10.1002\/ijc.31400 (2018).","journal-title":"Int. J. Cancer"},{"key":"19722_CR8","doi-asserted-by":"publisher","first-page":"122294","DOI":"10.1016\/j.lfs.2023.122294","volume":"336","author":"L Ye","year":"2024","unstructured":"Ye, L. et al. DCLK1 and its oncogenic functions: A promising therapeutic target for cancers. Life Sci. 336, 122294. https:\/\/doi.org\/10.1016\/j.lfs.2023.122294 (2024).","journal-title":"Life Sci."},{"key":"19722_CR9","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/s42003-021-02631-y","volume":"4","author":"O Patel","year":"2021","unstructured":"Patel, O. et al. Structural basis for small molecule targeting of doublecortin like kinase 1 with DCLK1-IN-1. Commun. Biol. 4, 1105. https:\/\/doi.org\/10.1038\/s42003-021-02631-y (2021).","journal-title":"Commun. Biol."},{"key":"19722_CR10","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1016\/j.str.2016.07.008","volume":"24","author":"O Patel","year":"2016","unstructured":"Patel, O. et al. Biochemical and structural insights into doublecortin-like kinase domain 1. Structure 24, 1550\u20131561. https:\/\/doi.org\/10.1016\/j.str.2016.07.008 (2016).","journal-title":"Structure"},{"key":"19722_CR11","doi-asserted-by":"publisher","unstructured":"Cheng, L. et al. DCLK1 autoinhibition and activation in tumorigenesis. Innov. (N Y). 3, 100191. https:\/\/doi.org\/10.1016\/j.xinn.2021.100191 (2022).","DOI":"10.1016\/j.xinn.2021.100191"},{"key":"19722_CR12","doi-asserted-by":"publisher","first-page":"100191","DOI":"10.1016\/j.xinn.2021.100191","volume":"3","author":"L Cheng","year":"2022","unstructured":"Cheng, L. et al. DCLK1 autoinhibition and activation in tumorigenesis. Innov. (N Y). 3, 100191. https:\/\/doi.org\/10.1016\/j.xinn.2021.100191 (2022).","journal-title":"Innov. (N Y)"},{"key":"19722_CR13","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1053\/j.gastro.2013.09.050","volume":"146","author":"JM Bailey","year":"2014","unstructured":"Bailey, J. M. et al. DCLK1 marks a morphologically distinct subpopulation of cells with stem cell properties in preinvasive pancreatic cancer. Gastroenterology 146, 245\u2013256. https:\/\/doi.org\/10.1053\/j.gastro.2013.09.050 (2014).","journal-title":"Gastroenterology"},{"key":"19722_CR14","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1002\/stem.193","volume":"27","author":"R May","year":"2009","unstructured":"May, R. et al. Doublecortin and cam kinase-like-1 and leucine-rich-repeat-containing G-protein-coupled receptor mark quiescent and cycling intestinal stem cells, respectively. Stem Cells. 27, 2571\u20132579. https:\/\/doi.org\/10.1002\/stem.193 (2009).","journal-title":"Stem Cells"},{"key":"19722_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12010054","author":"SM Sureban","year":"2019","unstructured":"Sureban, S. M. et al. DCLK1 monoclonal Antibody-Based CAR-T cells as a novel treatment strategy against human colorectal cancers. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers12010054 (2019).","journal-title":"Cancers (Basel)"},{"key":"19722_CR16","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/1476-4598-13-103","volume":"13","author":"N Weygant","year":"2014","unstructured":"Weygant, N. et al. Small molecule kinase inhibitor LRRK2-IN-1 demonstrates potent activity against colorectal and pancreatic cancer through Inhibition of doublecortin-like kinase 1. Mol. Cancer. 13, 103. https:\/\/doi.org\/10.1186\/1476-4598-13-103 (2014).","journal-title":"Mol. Cancer"},{"key":"19722_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11030990","author":"ALE Carli","year":"2023","unstructured":"Carli, A. L. E. et al. Structure-Guided prediction of the functional impact of DCLK1 mutations on tumorigenesis. Biomedicines https:\/\/doi.org\/10.3390\/biomedicines11030990 (2023).","journal-title":"Biomedicines"},{"key":"19722_CR18","doi-asserted-by":"publisher","first-page":"RP87958","DOI":"10.7554\/eLife.87958","volume":"12","author":"A Venkat","year":"2023","unstructured":"Venkat, A. et al. Mechanistic and evolutionary insights into isoform-specific \u2018supercharging\u2019 in DCLK family kinases. eLife 12, RP87958. https:\/\/doi.org\/10.7554\/eLife.87958 (2023).","journal-title":"eLife"},{"key":"19722_CR19","doi-asserted-by":"publisher","first-page":"8488","DOI":"10.3390\/ijms22168488","volume":"22","author":"DM Jang","year":"2021","unstructured":"Jang, D. M. et al. Structural basis of Inhibition of DCLK1 by ruxolitinib. Int. J. Mol. Sci. 22, 8488 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"19722_CR20","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1107\/s1744309111053164","volume":"68","author":"Y Kawaguchi","year":"2012","unstructured":"Kawaguchi, Y. et al. Crystallization and X-ray diffraction analysis of chondroitin lyase from baculovirus: Envelope protein ODV-E66. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 68, 190\u2013192. https:\/\/doi.org\/10.1107\/s1744309111053164 (2012).","journal-title":"Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun."},{"key":"19722_CR21","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1002\/kjm2.12578","volume":"38","author":"CH Hsieh","year":"2022","unstructured":"Hsieh, C. H. & Wang, Y. C. Emerging roles of plasma gelsolin in tumorigenesis and modulating the tumor microenvironment. Kaohsiung J. Med. Sci. 38, 819\u2013825. https:\/\/doi.org\/10.1002\/kjm2.12578 (2022).","journal-title":"Kaohsiung J. Med. Sci."},{"key":"19722_CR22","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1136\/gut.2005.083691","volume":"56","author":"CC Thompson","year":"2007","unstructured":"Thompson, C. C. et al. Pancreatic cancer cells overexpress gelsolin family-capping proteins, which contribute to their cell motility. Gut 56, 95\u2013106. https:\/\/doi.org\/10.1136\/gut.2005.083691 (2007).","journal-title":"Gut"},{"key":"19722_CR23","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1002\/kjm2.12578","volume":"38","author":"CH Hsieh","year":"2022","unstructured":"Hsieh, C. H. & Wang, Y. C. Emerging roles of plasma Gelsolin in tumorigenesis and modulating the tumor microenvironment. Kaohsiung J. Med. Sci. 38, 819\u2013825. https:\/\/doi.org\/10.1002\/kjm2.12578 (2022).","journal-title":"Kaohsiung J. Med. Sci."},{"key":"19722_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14041039","author":"M Asare-Werehene","year":"2022","unstructured":"Asare-Werehene, M. et al. Plasma Gelsolin confers chemoresistance in ovarian cancer by resetting the relative abundance and function of macrophage subtypes. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers14041039 (2022).","journal-title":"Cancers (Basel)"},{"key":"19722_CR25","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/s41419-023-05960-4","volume":"14","author":"B Yang","year":"2023","unstructured":"Yang, B. et al. Macrophage DCLK1 promotes obesity-induced cardiomyopathy via activating RIP2\/TAK1 signaling pathway. Cell. Death Dis. 14, 419. https:\/\/doi.org\/10.1038\/s41419-023-05960-4 (2023).","journal-title":"Cell. Death Dis."},{"key":"19722_CR26","doi-asserted-by":"publisher","first-page":"e17198","DOI":"10.15252\/emmm.202217198","volume":"15","author":"Z Huang","year":"2023","unstructured":"Huang, Z. et al. Macrophage DCLK1 promotes atherosclerosis via binding to IKKbeta and inducing inflammatory responses. EMBO Mol. Med. 15, e17198. https:\/\/doi.org\/10.15252\/emmm.202217198 (2023).","journal-title":"EMBO Mol. Med."},{"key":"19722_CR27","doi-asserted-by":"publisher","first-page":"e00967","DOI":"10.1128\/jvi.00967-22","volume":"96","author":"RB Undi","year":"2022","unstructured":"Undi, R. B. et al. Targeting doublecortin-like kinase 1 (DCLK1)-regulated SARS-CoV-2 pathogenesis in COVID-19. J. Virol. 96, e00967\u2013e00922 (2022). https:\/\/doi.org\/10.1128\/jvi.00967-22","journal-title":"J. Virol."},{"key":"19722_CR28","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/s41388-019-1056-3","volume":"39","author":"A Sorolla","year":"2020","unstructured":"Sorolla, A. et al. Precision medicine by designer interference peptides: Applications in oncology and molecular therapeutics. Oncogene 39, 1167\u20131184. https:\/\/doi.org\/10.1038\/s41388-019-1056-3 (2020).","journal-title":"Oncogene"},{"key":"19722_CR29","doi-asserted-by":"publisher","first-page":"5977","DOI":"10.1039\/D1SC00165E","volume":"12","author":"H Wang","year":"2021","unstructured":"Wang, H. et al. Peptide-based inhibitors of protein\u2013protein interactions: Biophysical, structural and cellular consequences of introducing a constraint. Chem. Sci. 12, 5977\u20135993. https:\/\/doi.org\/10.1039\/D1SC00165E (2021).","journal-title":"Chem. Sci."},{"key":"19722_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20102383","author":"AC Lee","year":"2019","unstructured":"Lee, A. C., Harris, J. L., Khanna, K. K. & Hong, J. H. A comprehensive review on current advances in peptide drug development and design. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms20102383 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"19722_CR31","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1038\/nrc2228","volume":"7","author":"C L\u00f3pez-Ot\u00edn","year":"2007","unstructured":"L\u00f3pez-Ot\u00edn, C. & Matrisian, L. M. Emerging roles of proteases in tumour suppression. Nat. Rev. Cancer. 7, 800\u2013808. https:\/\/doi.org\/10.1038\/nrc2228 (2007).","journal-title":"Nat. Rev. Cancer"},{"key":"19722_CR32","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.euprot.2014.05.003","volume":"4","author":"T Uhlig","year":"2014","unstructured":"Uhlig, T. et al. The emergence of peptides in the pharmaceutical business: From exploration to exploitation. EuPA Open. Proteom. 4, 58\u201369. https:\/\/doi.org\/10.1016\/j.euprot.2014.05.003 (2014). https:\/\/doi.org\/https:\/\/doi.org\/","journal-title":"EuPA Open. Proteom."},{"key":"19722_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17071023","author":"H Li","year":"2016","unstructured":"Li, H. et al. Roles of d-Amino acids on the bioactivity of host defense peptides. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms17071023 (2016).","journal-title":"Int. J. Mol. Sci."},{"key":"19722_CR34","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41392-022-00904-4","volume":"7","author":"L Wang","year":"2022","unstructured":"Wang, L. et al. Therapeutic peptides: Current applications and future directions. Signal. Transduct. Target. Therapy. 7, 48. https:\/\/doi.org\/10.1038\/s41392-022-00904-4 (2022).","journal-title":"Signal. Transduct. Target. Therapy"},{"key":"19722_CR35","doi-asserted-by":"publisher","first-page":"18","DOI":"10.4062\/biomolther.2019.082","volume":"28","author":"JS Choi","year":"2020","unstructured":"Choi, J. S. & Joo, S. H. Recent trends in cyclic peptides as therapeutic agents and biochemical tools. Biomol. Ther. (Seoul). 28, 18\u201324. https:\/\/doi.org\/10.4062\/biomolther.2019.082 (2020).","journal-title":"Biomol. Ther. (Seoul)"},{"key":"19722_CR36","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1073\/pnas.251687998","volume":"99","author":"M Essler","year":"2002","unstructured":"Essler, M. & Ruoslahti, E. Molecular specialization of breast vasculature: A breast-homing phage-displayed peptide binds to aminopeptidase P in breast vasculature. Proc. Natl. Acad. Sci. U S A. 99, 2252\u20132257. https:\/\/doi.org\/10.1073\/pnas.251687998 (2002).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"19722_CR37","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1021\/bc0701139","volume":"19","author":"H Myrberg","year":"2008","unstructured":"Myrberg, H., Zhang, L., M\u00e4e, M. & Langel, U. Design of a tumor-homing cell-penetrating peptide. Bioconjug. Chem. 19, 70\u201375. https:\/\/doi.org\/10.1021\/bc0701139 (2008).","journal-title":"Bioconjug. Chem."},{"key":"19722_CR38","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1021\/acs.bioconjchem.5b00481","volume":"27","author":"A Cordova","year":"2016","unstructured":"Cordova, A. et al. Aminopeptidase P mediated targeting for breast tissue specific conjugate delivery. Bioconjug. Chem. 27, 1981\u20131990. https:\/\/doi.org\/10.1021\/acs.bioconjchem.5b00481 (2016).","journal-title":"Bioconjug. Chem."},{"key":"19722_CR39","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/bip.360370303","volume":"37","author":"M Lebl","year":"1995","unstructured":"Lebl, M. et al. One-bead-one-structure combinatorial libraries. Biopolymers 37, 177\u2013198. https:\/\/doi.org\/10.1002\/bip.360370303 (1995).","journal-title":"Biopolymers"},{"key":"19722_CR40","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1158\/1535-7163.Mct-19-0776","volume":"19","author":"P Chandrakesan","year":"2020","unstructured":"Chandrakesan, P. et al. DCLK1-Isoform2 alternative splice variant promotes pancreatic tumor immunosuppressive M2-Macrophage polarization. Mol. Cancer Ther. 19, 1539\u20131549. https:\/\/doi.org\/10.1158\/1535-7163.Mct-19-0776 (2020).","journal-title":"Mol. Cancer Ther."},{"key":"19722_CR41","doi-asserted-by":"publisher","first-page":"30876","DOI":"10.18632\/oncotarget.5129","volume":"6","author":"P Chandrakesan","year":"2015","unstructured":"Chandrakesan, P. et al. Dclk1\u2009+\u2009small intestinal epithelial tuft cells display the hallmarks of quiescence and self-renewal. Oncotarget 6, 30876\u201330886. https:\/\/doi.org\/10.18632\/oncotarget.5129 (2015).","journal-title":"Oncotarget"},{"key":"19722_CR42","doi-asserted-by":"publisher","first-page":"9269","DOI":"10.18632\/oncotarget.2393","volume":"5","author":"P Chandrakesan","year":"2014","unstructured":"Chandrakesan, P. et al. DCLK1 facilitates intestinal tumor growth via enhancing pluripotency and epithelial mesenchymal transition. Oncotarget 5, 9269\u20139280. https:\/\/doi.org\/10.18632\/oncotarget.2393 (2014).","journal-title":"Oncotarget"},{"key":"19722_CR43","doi-asserted-by":"publisher","first-page":"e1000412","DOI":"10.1371\/journal.pbio.1000412","volume":"8","author":"C Kilkenny","year":"2010","unstructured":"Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M. & Altman, D. G. Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research. PLoS Biol. 8, e1000412. https:\/\/doi.org\/10.1371\/journal.pbio.1000412 (2010).","journal-title":"PLoS Biol."},{"key":"19722_CR44","doi-asserted-by":"publisher","first-page":"13713","DOI":"10.1073\/pnas.0812374106","volume":"106","author":"S Nag","year":"2009","unstructured":"Nag, S. et al. Ca2\u2009+\u2009binding by domain 2 plays a critical role in the activation and stabilization of Gelsolin. Proc. Natl. Acad. Sci. U S A. 106, 13713\u201313718. https:\/\/doi.org\/10.1073\/pnas.0812374106 (2009).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"19722_CR45","unstructured":"mgl-admin. AutoDock, https:\/\/autodock.scripps.edu."},{"key":"19722_CR46","doi-asserted-by":"publisher","first-page":"W419","DOI":"10.1093\/nar\/gkv456","volume":"43","author":"M Kurcinski","year":"2015","unstructured":"Kurcinski, M., Jamroz, M., Blaszczyk, M., Kolinski, A. & Kmiecik, S. CABS-dock web server for the flexible docking of peptides to proteins without prior knowledge of the binding site. Nucleic Acids Res. 43, W419\u2013W424. https:\/\/doi.org\/10.1093\/nar\/gkv456 (2015).","journal-title":"Nucleic Acids Res."},{"key":"19722_CR47","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/978-1-4939-7756-7_18","volume":"1762","author":"LP Morency","year":"2018","unstructured":"Morency, L. P., Gaudreault, F. & Najmanovich, R. Applications of the NRGsuite and the molecular docking software flexaid in computational drug discovery and design. Methods Mol. Biol. 1762, 367\u2013388. https:\/\/doi.org\/10.1007\/978-1-4939-7756-7_18 (2018).","journal-title":"Methods Mol. Biol."},{"key":"19722_CR48","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/978-1-4939-9608-7_9","volume":"2022","author":"L Wang","year":"2019","unstructured":"Wang, L., Chambers, J. & Abel, R. Protein-Ligand binding free energy calculations with FEP. Methods Mol. Biol. 2022, 201\u2013232. https:\/\/doi.org\/10.1007\/978-1-4939-9608-7_9 (2019).","journal-title":"Methods Mol. Biol."},{"key":"19722_CR49","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.cell.2016.07.005","volume":"166","author":"IY Park","year":"2016","unstructured":"Park, I. Y. et al. Dual chromatin and cytoskeletal remodeling by SETD2. Cell 166, 950\u2013962. https:\/\/doi.org\/10.1016\/j.cell.2016.07.005 (2016).","journal-title":"Cell"},{"key":"19722_CR50","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2174\/1568009618666180319091731","volume":"19","author":"L Lang","year":"2019","unstructured":"Lang, L., Shull, A. Y. & Teng, Y. Interrupting the FGF19-FGFR4 axis to therapeutically disrupt cancer progression. Curr. Cancer Drug Targets. 19, 17\u201325. https:\/\/doi.org\/10.2174\/1568009618666180319091731 (2019).","journal-title":"Curr. Cancer Drug Targets"},{"key":"19722_CR51","doi-asserted-by":"publisher","first-page":"24424","DOI":"10.18632\/aging.202300","volume":"12","author":"Y Yang","year":"2020","unstructured":"Yang, Y. et al. FOXM1\/DVL2\/Snail axis drives metastasis and chemoresistance of colorectal cancer. Aging (Albany NY). 12, 24424\u201324440. https:\/\/doi.org\/10.18632\/aging.202300 (2020).","journal-title":"Aging (Albany NY)"},{"key":"19722_CR52","doi-asserted-by":"publisher","first-page":"1980368","DOI":"10.1155\/2020\/1980368","volume":"2020","author":"Y Zhang","year":"2020","unstructured":"Zhang, Y. et al. Gelsolin promotes cancer progression by regulating epithelial-mesenchymal transition in hepatocellular carcinoma and correlates with a poor prognosis. J. Oncol 2020, 1980368. https:\/\/doi.org\/10.1155\/2020\/1980368 (2020).","journal-title":"J. Oncol."},{"key":"19722_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11060808","author":"I Dufait","year":"2019","unstructured":"Dufait, I. et al. Perforin and granzyme B expressed by murine Myeloid-Derived suppressor cells: A study on their role in outgrowth of cancer cells. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers11060808 (2019).","journal-title":"Cancers (Basel)"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19722-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19722-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19722-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T03:24:39Z","timestamp":1760844279000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19722-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["19722"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-19722-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6099914\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"assertion":[{"value":"24 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Courtney W. Houchen has an ownership interest in COARE Holdings, Inc., and M.L.B. is a co-founder of Trocar Pharmaceuticals and of Shuttle Pharmaceuticals. The remaining authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"35811"}}